Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01024231 · ClinicalTrials.gov registry record · Phase 1
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 127
- Enrollment target
NCT01024231 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 127 participants.
The verdict
NCT01024231, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 127 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of treatment with BMS-936558 (MDX-1106) in combination with Ipilimumab (BMS-734016) when given at the same time or as a sequenced regimen in subjects with unresectable Stage III or Stage IV malignant melanoma (MEL)
Interventions
- DRUG Ipilimumab
- DRUG BMS-936558 (MDX1106-04)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2009-12-14 |
| Est. Completion | 2019-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01024231
The ClinicalTrials.gov registry entry for NCT01024231 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT01024231 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01024231 about?
NCT01024231 is a clinical study titled "Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma". The purpose of this study is to determine the safety and tolerability of treatment with BMS-936558 (MDX-1106) in combination with Ipilimumab (BMS-734016) when given at the same time or as a sequenced regimen in subjects with unresectable Stage III or Stage IV malignant melanoma (MEL)
What is the current status of trial NCT01024231?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 127 participants. The study started on 2009-12-14. Estimated completion is 2019-04-01.
What interventions are being tested in trial NCT01024231?
The interventions under investigation include: Ipilimumab (DRUG), BMS-936558 (MDX1106-04) (DRUG).
Who is sponsoring clinical trial NCT01024231?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.